Cellectis (CLLS) EBT Growth (1y) (2016 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBT Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 88.92% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.23% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 213.87% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 530.43% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.45% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -200.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -200.75% |
| Mar 31, 2026 | -473.36% |
| Dec 31, 2025 | 89.74% |
| Sep 30, 2025 | 666.75% |
| Jun 30, 2025 | 161.39% |
| Mar 31, 2025 | -79.70% |
| Dec 31, 2024 | 67.56% |
| Sep 30, 2024 | 548.31% |
| Jun 30, 2024 | -638.43% |
| Mar 31, 2024 | 153.25% |
| Dec 31, 2023 | -4,061.65% |
| Sep 30, 2023 | 97.21% |
| Jun 30, 2023 | 124.91% |
| Mar 31, 2023 | -289.41% |
| Dec 31, 2022 | 59.80% |
| Sep 30, 2022 | 44.84% |
| Jun 30, 2022 | 49.28% |
| Mar 31, 2022 | 43.97% |
| Dec 31, 2021 | -118.02% |
| Sep 30, 2021 | -44.34% |